Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

The aim of the study is to assess the prevalence of vitamin D deficiency in a well-characterized IBD cohort in Western Greece, and explore its associations with clinical features, laboratory biomarkers, and treatment intensity.

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Cross-sectional study.

Cross-sectional study

Examines a population at a particular point in time.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Methods: In this cross-sectional study, 184 consecutive, well-characterized IBD outpatients followed at a tertiary referral center in Western Greece underwent clinical evaluation and laboratory testing between January 2023 and December 2024.

Source: Abstract.

All participants were treated according to the European Crohn’s and Colitis Organization’s (ECCO) guidelines.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

High Prevalence and Clinical Associations of Vitamin D Deficiency in Inflammatory Bowel Disease: Evidence from a Tertiary Center Cohort

Cross-sectional study · Nutrients · 2025

Original publication title

High Prevalence and Clinical Associations of Vitamin D Deficiency in Inflammatory Bowel Disease: Evidence from a Tertiary Center Cohort

Theodora Kafentzi; Ploutarchos Pastras; Ioanna Aggeletopoulou; Efthymios P. Tsounis; Georgios Geramoutsos; Nikitas Kimiskidis; Maria Bali; Konstantinos Thomopoulos; Georgia Diamantopoulou; Georgios Theocharis; Christos Triantos

© 2025 by the authors.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Background/Objectives:

Vitamin D in its active form, 1,25-dihydroxyvitamin D3 [1,25(OH)2D3], plays a critical role in immune regulation, gut barrier function, and systemic inflammation. Its deficiency is frequent in Inflammatory Bowel Disease (IBD), but the clinical implications remain uncertain. The aim of the study is to assess the prevalence of vitamin D deficiency in a well-characterized IBD cohort in Western Greece, and explore its associations with clinical features, laboratory biomarkers, and treatment intensity.

Methods:

In this cross-sectional study, 184 consecutive, well-characterized IBD outpatients followed at a tertiary referral center in Western Greece underwent clinical evaluation and laboratory testing between January 2023 and December 2024. Vitamin D is determined by measuring 25-hydroxyvitamin D [25(OH)D], which reflects the body’s vitamin D stores due to its longer half-life compared with the biologically active form. Deficiency was defined as serum 25(OH)D < 20 ng/mL. Associations with disease type, clinical and laboratory biomarkers, severity indices, and treatment were analyzed using multivariate logistic regression.

Results:

Vitamin D deficiency was identified in 67 patients (36.4%). Although unrelated to disease type, hospitalization, surgery, or disease activity indices, deficiency correlated with systemic inflammation, nutrition/metabolic markers, and treatment intensity. More specifically, vitamin D-deficient patients exhibited higher platelet counts (p = 0.005) and erythrocyte sedimentation rate (ESR) (p = 0.014), lower hemoglobin (p = 0.005), albumin (p = 0.011), and serum glutamic-oxaloacetic transaminase (SGOT) (p = 0.009) levels and more frequent use of biologic therapy (p = 0.009). In multivariate analysis, vitamin D deficiency remained independently associated with biologic therapy (aOR = 0.374; 95% CI: 0.148 to 0.946), platelet count (aOR = 0.996, 95% CI: 0.992 to 0.999), and SGOT (aOR = 1.05, 95% CI: 1.00 to 1.10), indicating consistent links between vitamin D deficiency and treatment intensity, systemic inflammation, and nutritional or metabolic status.

Conclusions:

Vitamin D deficiency is common among IBD patients and independently associates with systemic inflammation, metabolic impairment, and intensified treatment requirement, supporting its potential role as a marker of disease burden.

An extract from the source publication. Read it in context.

At a glance

Abstract: Background/Objectives

Vitamin D in its active form, 1,25-dihydroxyvitamin D3 [1,25(OH)2D3], plays a critical role in immune regulation, gut barrier function, and systemic inflammation. Its deficiency is frequent in Inflammatory Bowel Disease (IBD), but the clinical implications remain uncertain. The aim of the study is to assess the prevalence of vitamin D deficiency in a well-characterized IBD cohort in Western Greece, and explore its associations with clinical features, laboratory biomarkers, and treatment intensity.

Source: Background/Objectives:

Abstract: Results

Vitamin D deficiency was identified in 67 patients (36.4%). Although unrelated to disease type, hospitalization, surgery, or disease activity indices, deficiency correlated with systemic inflammation, nutrition/metabolic markers, and treatment intensity. More specifically, vitamin D-deficient patients exhibited higher platelet counts (p = 0.005) and erythrocyte sedimentation rate (ESR) (p = 0.014), lower hemoglobin (p = 0.005), albumin (p = 0.011), and serum glutamic-oxaloacetic transaminase (SGOT) (p = 0.009) levels and more frequent use of biologic therapy (p = 0.009). In multivariate analysis, vitamin D deficiency remained independently associated with biologic therapy (aOR = 0.374; 95% CI: 0.148 to 0.946), platelet count (aOR = 0.996, 95% CI: 0.992 to 0.999), and SGOT (aOR = 1.05, 95% CI: 1.00 to 1.10), indicating consistent links between vitamin D deficiency and treatment intensity, systemic inflammation, and nutritional or metabolic status.

Source: Results:

Abstract: Conclusions

Vitamin D deficiency is common among IBD patients and independently associates with systemic inflammation, metabolic impairment, and intensified treatment requirement, supporting its potential role as a marker of disease burden.

Source: Conclusions:
Authors’ abstract

Background/Objectives:

Vitamin D in its active form, 1,25-dihydroxyvitamin D3 [1,25(OH)2D3], plays a critical role in immune regulation, gut barrier function, and systemic inflammation. Its deficiency is frequent in Inflammatory Bowel Disease (IBD), but the clinical implications remain uncertain. The aim of the study is to assess the prevalence of vitamin D deficiency in a well-characterized IBD cohort in Western Greece, and explore its associations with clinical features, laboratory biomarkers, and treatment intensity.

Methods:

In this cross-sectional study, 184 consecutive, well-characterized IBD outpatients followed at a tertiary referral center in Western Greece underwent clinical evaluation and laboratory testing between January 2023 and December 2024. Vitamin D is determined by measuring 25-hydroxyvitamin D [25(OH)D], which reflects the body’s vitamin D stores due to its longer half-life compared with the biologically active form. Deficiency was defined as serum 25(OH)D < 20 ng/mL. Associations with disease type, clinical and laboratory biomarkers, severity indices, and treatment were analyzed using multivariate logistic regression.

Results:

Vitamin D deficiency was identified in 67 patients (36.4%). Although unrelated to disease type, hospitalization, surgery, or disease activity indices, deficiency correlated with systemic inflammation, nutrition/metabolic markers, and treatment intensity. More specifically, vitamin D-deficient patients exhibited higher platelet counts (p = 0.005) and erythrocyte sedimentation rate (ESR) (p = 0.014), lower hemoglobin (p = 0.005), albumin (p = 0.011), and serum glutamic-oxaloacetic transaminase (SGOT) (p = 0.009) levels and more frequent use of biologic therapy (p = 0.009). In multivariate analysis, vitamin D deficiency remained independently associated with biologic therapy (aOR = 0.374; 95% CI: 0.148 to 0.946), platelet count (aOR = 0.996, 95% CI: 0.992 to 0.999), and SGOT (aOR = 1.05, 95% CI: 1.00 to 1.10), indicating consistent links between vitamin D deficiency and treatment intensity, systemic inflammation, and nutritional or metabolic status.

Conclusions:

Vitamin D deficiency is common among IBD patients and independently associates with systemic inflammation, metabolic impairment, and intensified treatment requirement, supporting its potential role as a marker of disease burden.

Publication and source details

Original title: High Prevalence and Clinical Associations of Vitamin D Deficiency in Inflammatory Bowel Disease: Evidence from a Tertiary Center Cohort

Theodora Kafentzi; Ploutarchos Pastras; Ioanna Aggeletopoulou; Efthymios P. Tsounis; Georgios Geramoutsos; Nikitas Kimiskidis; Maria Bali; Konstantinos Thomopoulos; Georgia Diamantopoulou; Georgios Theocharis; Christos Triantos

Nutrients · 2025

* Correspondence: chtriantos@upatras.gr or chtriantos@hotmail.com; Tel.: +30-6-972-894-651© 2025 by the authors.2025https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).This research received no external funding.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T00:45:20.261864+00:00

DOI: 10.3390/nu17233698 · PMC12694141